The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. First, the sensitivity and IC values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using th...
Saved in:
Published in | OncoTargets and therapy Vol. 13; pp. 3823 - 3837 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove
01.01.2020
Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines.
First, the sensitivity and IC
values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using the CCK-8 assay. Then, the relatively insensitive gastric cancer cell lines (MGC-803 and BGC-823) were treated with low concentrations of chidamide alone, bortezomib alone, or chidamide and bortezomib combination to detect the effects on cell proliferation, apoptosis, migration, and invasion. Finally, the inhibitory effect of the combined chidamide and bortezomib treatment on MGC-803 cells was verified in vivo through tumor formation experiments in nude mice.
Compared with low-dose chidamide or bortezomib alone, the low-dose drug combination significantly inhibited the proliferation, migration, and invasion of MGC-803 and BGC-823 cells and induced apoptosis of the cells. The effects of the low-dose chidamide and bortezomib combination reduced the growth on gastric cancer in vivo were investigated by using a subcutaneous tumor mouse model.
Our results suggest that the combination of chidamide and bortezomib can significantly reduce the proliferation, invasion, and migration of MGC-803 and BGC-823 cells, providing a framework for the clinical evaluation of combined therapies for gastric cancers. |
---|---|
AbstractList | Wanjun Zhang,1,* Junwei Niu,1,* Yongcheng Ma,2 Xiawan Yang,1 Huixia Cao,3 Honggang Guo,1 Fengchang Bao,1 Ahmed Haw,1 Yuqing Chen,1 Kai Sun1 1Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China; 2Clinical Pharmacology Laboratory, Henan Provincial People's Hospital; Department of Pharmacy of Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan 450003, People's Republic of China; 3Department of Nephrology, Henan Key Library for Kidney Disease and Immunology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, People's Republic of China*These authors contributed equally to this workCorrespondence: Kai Sun; Yuqing ChenDepartment of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, People's Republic of ChinaTel/Fax +86 371 65580798Email sunkai@cellscience.org; henanblood@sina.comPurpose: The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines.Materials and Methods: First, the sensitivity and IC50 values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using the CCK-8 assay. Then, the relatively insensitive gastric cancer cell lines (MGC-803 and BGC-823) were treated with low concentrations of chidamide alone, bortezomib alone, or chidamide and bortezomib combination to detect the effects on cell proliferation, apoptosis, migration, and invasion. Finally, the inhibitory effect of the combined chidamide and bortezomib treatment on MGC-803 cells was verified in vivo through tumor formation experiments in nude mice.Results: Compared with low-dose chidamide or bortezomib alone, the low-dose drug combination significantly inhibited the proliferation, migration, and invasion of MGC-803 and BGC-823 cells and induced apoptosis of the cells. The effects of the low-dose chidamide and bortezomib combination reduced the growth on gastric cancer in vivo were investigated by using a subcutaneous tumor mouse model.Conclusion: Our results suggest that the combination of chidamide and bortezomib can significantly reduce the proliferation, invasion, and migration of MGC-803 and BGC-823 cells, providing a framework for the clinical evaluation of combined therapies for gastric cancers.Keywords: chidamide, bortezomib, combination drug therapy, gastric cancer PURPOSEThe aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. MATERIALS AND METHODSFirst, the sensitivity and IC50 values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using the CCK-8 assay. Then, the relatively insensitive gastric cancer cell lines (MGC-803 and BGC-823) were treated with low concentrations of chidamide alone, bortezomib alone, or chidamide and bortezomib combination to detect the effects on cell proliferation, apoptosis, migration, and invasion. Finally, the inhibitory effect of the combined chidamide and bortezomib treatment on MGC-803 cells was verified in vivo through tumor formation experiments in nude mice. RESULTSCompared with low-dose chidamide or bortezomib alone, the low-dose drug combination significantly inhibited the proliferation, migration, and invasion of MGC-803 and BGC-823 cells and induced apoptosis of the cells. The effects of the low-dose chidamide and bortezomib combination reduced the growth on gastric cancer in vivo were investigated by using a subcutaneous tumor mouse model. CONCLUSIONOur results suggest that the combination of chidamide and bortezomib can significantly reduce the proliferation, invasion, and migration of MGC-803 and BGC-823 cells, providing a framework for the clinical evaluation of combined therapies for gastric cancers. The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. First, the sensitivity and IC values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using the CCK-8 assay. Then, the relatively insensitive gastric cancer cell lines (MGC-803 and BGC-823) were treated with low concentrations of chidamide alone, bortezomib alone, or chidamide and bortezomib combination to detect the effects on cell proliferation, apoptosis, migration, and invasion. Finally, the inhibitory effect of the combined chidamide and bortezomib treatment on MGC-803 cells was verified in vivo through tumor formation experiments in nude mice. Compared with low-dose chidamide or bortezomib alone, the low-dose drug combination significantly inhibited the proliferation, migration, and invasion of MGC-803 and BGC-823 cells and induced apoptosis of the cells. The effects of the low-dose chidamide and bortezomib combination reduced the growth on gastric cancer in vivo were investigated by using a subcutaneous tumor mouse model. Our results suggest that the combination of chidamide and bortezomib can significantly reduce the proliferation, invasion, and migration of MGC-803 and BGC-823 cells, providing a framework for the clinical evaluation of combined therapies for gastric cancers. |
Author | Haw, Ahmed Bao, Fengchang Ma, Yongcheng Yang, Xiawan Chen, Yuqing Sun, Kai Zhang, Wanjun Niu, Junwei Cao, Huixia Guo, Honggang |
Author_xml | – sequence: 1 givenname: Wanjun surname: Zhang fullname: Zhang, Wanjun organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 2 givenname: Junwei surname: Niu fullname: Niu, Junwei organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 3 givenname: Yongcheng surname: Ma fullname: Ma, Yongcheng organization: Clinical Pharmacology Laboratory, Henan Provincial People's Hospital; Department of Pharmacy of Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan 450003, People's Republic of China – sequence: 4 givenname: Xiawan orcidid: 0000-0002-2183-2741 surname: Yang fullname: Yang, Xiawan organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 5 givenname: Huixia surname: Cao fullname: Cao, Huixia organization: Department of Nephrology, Henan Key Library for Kidney Disease and Immunology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, People's Republic of China – sequence: 6 givenname: Honggang surname: Guo fullname: Guo, Honggang organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 7 givenname: Fengchang surname: Bao fullname: Bao, Fengchang organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 8 givenname: Ahmed orcidid: 0000-0002-5071-8251 surname: Haw fullname: Haw, Ahmed organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 9 givenname: Yuqing surname: Chen fullname: Chen, Yuqing organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China – sequence: 10 givenname: Kai surname: Sun fullname: Sun, Kai organization: Department of Hematology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, People's Republic of China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32440150$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU1r3DAQhkVJaT7aU-9Fx0LZVLJsy3spbEyaBgI5xHd1JI13FWwplbQp219fpbsNyUnDzMujGZ5TcuSDR0I-cnZe8Vp-vR2G87uqZrLib8gJ57JbtEvBjl7Ux-Q0pXvG2rar6nfkWFR1zXjDTsjPYYP0bucxrl3KztCVzy5v5xDpymT36PKOhpH2G2dhdhap87QPs3Yesgue_nZ5Qy9CzPgnzE7T0rqClGMh9eANxvfk7QhTwg-H94wM3y-H_sfi5vbqul_dLEwjeF4Y1mlmOVRjg1ZX0hgheQPALZecLQFaaVs5CiugW2rd6VFDLbsyBAZ2Kc7I9R5rA9yrh-hmiDsVwKl_jRDXCmK5b0LF26ZDU-u6KQgUFoy1ohvHiosGkWNhfduzHrZ6RmvQ5wjTK-jriXcbtQ6PqhgQdSUL4PMBEMOvLaasZpcMThN4DNukiqxWMF4clOiXfdTEkFLE8fkbztSTXlX0qoPekv70crPn7H-f4i-1pqSA |
CitedBy_id | crossref_primary_10_1007_s11010_022_04584_0 crossref_primary_10_3389_fphar_2022_1096055 crossref_primary_10_1021_acsami_1c08290 crossref_primary_10_1080_14737159_2022_2159381 crossref_primary_10_3389_fgene_2023_1118889 crossref_primary_10_1007_s11095_022_03291_1 crossref_primary_10_1124_jpet_123_001583 crossref_primary_10_3389_fcell_2021_685954 crossref_primary_10_1016_j_dyepig_2022_110174 crossref_primary_10_1245_s10434_021_10945_8 |
Cites_doi | 10.1007/s40264-018-0773-9 10.1038/sj.leu.2402417 10.1016/j.phrs.2018.11.035 10.1038/sj.onc.1210029 10.3389/fonc.2019.00249 10.1007/s10495-006-0025-9 10.7150/jca.28570 10.1158/1078-0432.CCR-03-0806 10.1002/cam4.2474 10.3892/mmr.2012.858 10.1097/CAD.0b013e32808bf9d8 10.1158/0008-5472.CAN-06-4274 10.1158/1078-0432.CCR-04-0229 10.4161/15592294.2014.983367 10.3389/fphar.2019.00820 10.1016/j.jtcvs.2010.01.039 10.1158/1078-0432.CCR-06-0170 10.1093/annonc/mdv237 10.1152/physrev.00027.2001 10.1158/1078-0432.CCR-08-2365 10.1016/j.tcb.2013.03.002 10.3892/or.2014.3595 10.2174/156800961506150805153230 10.3390/cancers11030399 10.1016/S0305-7372(03)00082-3 10.1093/jnci/92.15.1210 10.1016/j.bbrc.2013.03.059 10.1002/ijc.27947 10.1016/S0022-5223(03)01321-7 10.1016/j.bbrc.2010.01.011 10.3322/caac.21492 10.1634/theoncologist.12-10-1247 10.1158/0008-5472.CAN-16-1974 10.1016/j.biopha.2014.03.011 10.1038/nrc2620 10.1016/S1470-2045(14)70440-1 |
ContentType | Journal Article |
Copyright | 2020 Zhang et al. 2020 Zhang et al. 2020 Zhang et al. |
Copyright_xml | – notice: 2020 Zhang et al. – notice: 2020 Zhang et al. 2020 Zhang et al. |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.2147/OTT.S240721 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Zhang et al |
EISSN | 1178-6930 |
EndPage | 3837 |
ExternalDocumentID | oai_doaj_org_article_1658ec4b45ba4e3dacdd38ff2135ee1e 10_2147_OTT_S240721 32440150 |
Genre | Journal Article |
GroupedDBID | --- 0YH 29N 2WC 53G 5VS 7X7 8FE 8FH 8FI 8FJ 8G5 ABDBF ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HMCUK HYE IAO IHR IHW IPNFZ ITC KQ8 LK8 M2O M48 M7P M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RNS RPM TR2 TUS UKHRP VDV AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c531t-c08b0d1a2f5edb27cc3715aa1d17109aa67d67f3d3a89bb8bfba478171a0ad93 |
IEDL.DBID | RPM |
ISSN | 1178-6930 |
IngestDate | Fri Oct 04 13:07:19 EDT 2024 Tue Sep 17 20:55:19 EDT 2024 Fri Aug 16 22:56:52 EDT 2024 Thu Sep 26 17:20:26 EDT 2024 Sat Sep 28 08:20:24 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | chidamide gastric cancer bortezomib combination drug therapy |
Language | English |
License | 2020 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c531t-c08b0d1a2f5edb27cc3715aa1d17109aa67d67f3d3a89bb8bfba478171a0ad93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
ORCID | 0000-0002-2183-2741 0000-0002-5071-8251 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213427/ |
PMID | 32440150 |
PQID | 2406301440 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_1658ec4b45ba4e3dacdd38ff2135ee1e pubmedcentral_primary_oai_pubmedcentral_nih_gov_7213427 proquest_miscellaneous_2406301440 crossref_primary_10_2147_OTT_S240721 pubmed_primary_32440150 |
PublicationCentury | 2000 |
PublicationDate | 2020-01-01 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | OncoTargets and therapy |
PublicationTitleAlternate | Onco Targets Ther |
PublicationYear | 2020 |
Publisher | Dove Dove Medical Press |
Publisher_xml | – name: Dove – name: Dove Medical Press |
References | Shi (ref30) 2015; 26 Zhao (ref31) 2015; 33 Lenz (ref16) 2003; 29 Suppl 1 Bray (ref1) 2018; 68 Glickman (ref14) 2002; 82 Huang (ref22) 2019; 9 Shah (ref7) 2019; 42 San-Miguel (ref8) 2014; 15 Tay (ref32) 2019; 10 Harashima (ref35) 2013; 23 Tew (ref17) 2016; 76 Mithraprabhu (ref5) 2014; 9 Li (ref28) 2015; 15 Petrillo (ref2) 2019; 11 Zhao (ref29) 2016; 8 Denlinger (ref23) 2004; 127 Zhou (ref11) 2014; 68 Polyak (ref36) 2009; 9 Dillekas (ref3) 2019; 8 Xing (ref39) 2013; 132 Saulle (ref20) 2007; 12 Zhang (ref24) 2019; 10 Almond (ref15) 2002; 16 Mann (ref6) 2007; 12 Liu (ref9) 2010; 392 Adachi (ref27) 2004; 10 Qiao (ref12) 2013; 434 Bhalla (ref26) 2009; 15 Mao (ref13) 2018; 10 Liu (ref21) 2007; 67 Haddad (ref33) 2004; 10 Herzig (ref37) 2007; 26 Marks (ref4) 2000; 92 Kane (ref18) 2006; 12 Taylor (ref38) 2010; 139 Roskoski (ref34) 2019; 139 Wang (ref10) 2012; 5 Fujita (ref19) 2007; 18 Xu (ref25) 2019; 11 |
References_xml | – volume: 42 start-page: 235 year: 2019 ident: ref7 publication-title: Drug Safety doi: 10.1007/s40264-018-0773-9 contributor: fullname: Shah – volume: 16 start-page: 433 year: 2002 ident: ref15 publication-title: Leukemia doi: 10.1038/sj.leu.2402417 contributor: fullname: Almond – volume: 139 start-page: 471 year: 2019 ident: ref34 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2018.11.035 contributor: fullname: Roskoski – volume: 26 start-page: 2290 year: 2007 ident: ref37 publication-title: Oncogene doi: 10.1038/sj.onc.1210029 contributor: fullname: Herzig – volume: 9 start-page: 249 year: 2019 ident: ref22 publication-title: Front Oncol doi: 10.3389/fonc.2019.00249 contributor: fullname: Huang – volume: 12 start-page: 635 year: 2007 ident: ref20 publication-title: Apoptosis doi: 10.1007/s10495-006-0025-9 contributor: fullname: Saulle – volume: 10 start-page: 1275 year: 2019 ident: ref24 publication-title: J Cancer doi: 10.7150/jca.28570 contributor: fullname: Zhang – volume: 10 start-page: 3853 year: 2004 ident: ref27 publication-title: Clinical Cancer Res doi: 10.1158/1078-0432.CCR-03-0806 contributor: fullname: Adachi – volume: 8 start-page: 5574 year: 2019 ident: ref3 publication-title: Cancer Med doi: 10.1002/cam4.2474 contributor: fullname: Dillekas – volume: 5 start-page: 1503 year: 2012 ident: ref10 publication-title: Mol Med Rep doi: 10.3892/mmr.2012.858 contributor: fullname: Wang – volume: 18 start-page: 677 year: 2007 ident: ref19 publication-title: Anticancer Drugs doi: 10.1097/CAD.0b013e32808bf9d8 contributor: fullname: Fujita – volume: 67 start-page: 4981 year: 2007 ident: ref21 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-4274 contributor: fullname: Liu – volume: 8 start-page: 3169 year: 2016 ident: ref29 publication-title: Am J Transl Res contributor: fullname: Zhao – volume: 10 start-page: 4680 year: 2004 ident: ref33 publication-title: Clinical Cancer Res doi: 10.1158/1078-0432.CCR-04-0229 contributor: fullname: Haddad – volume: 9 start-page: 1511 year: 2014 ident: ref5 publication-title: Epigenetics doi: 10.4161/15592294.2014.983367 contributor: fullname: Mithraprabhu – volume: 10 year: 2019 ident: ref32 publication-title: Front Pharmacol doi: 10.3389/fphar.2019.00820 contributor: fullname: Tay – volume: 139 start-page: 1224 year: 2010 ident: ref38 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2010.01.039 contributor: fullname: Taylor – volume: 12 start-page: 2955 year: 2006 ident: ref18 publication-title: Clinical Cancer Res doi: 10.1158/1078-0432.CCR-06-0170 contributor: fullname: Kane – volume: 26 start-page: 1766 year: 2015 ident: ref30 publication-title: Ann Oncol doi: 10.1093/annonc/mdv237 contributor: fullname: Shi – volume: 82 start-page: 373 year: 2002 ident: ref14 publication-title: Physiol Rev doi: 10.1152/physrev.00027.2001 contributor: fullname: Glickman – volume: 15 start-page: 3354 year: 2009 ident: ref26 publication-title: Clinical Cancer Res doi: 10.1158/1078-0432.CCR-08-2365 contributor: fullname: Bhalla – volume: 23 start-page: 345 year: 2013 ident: ref35 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2013.03.002 contributor: fullname: Harashima – volume: 33 start-page: 304 year: 2015 ident: ref31 publication-title: Oncol Rep doi: 10.3892/or.2014.3595 contributor: fullname: Zhao – volume: 15 start-page: 493 year: 2015 ident: ref28 publication-title: Curr Cancer Drug Targets doi: 10.2174/156800961506150805153230 contributor: fullname: Li – volume: 11 start-page: 399 year: 2019 ident: ref2 publication-title: Cancers doi: 10.3390/cancers11030399 contributor: fullname: Petrillo – volume: 29 Suppl 1 start-page: 41 year: 2003 ident: ref16 publication-title: Cancer Treat Rev doi: 10.1016/S0305-7372(03)00082-3 contributor: fullname: Lenz – volume: 92 start-page: 1210 year: 2000 ident: ref4 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.15.1210 contributor: fullname: Marks – volume: 434 start-page: 95 year: 2013 ident: ref12 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2013.03.059 contributor: fullname: Qiao – volume: 132 start-page: 2589 year: 2013 ident: ref39 publication-title: Int J Cancer doi: 10.1002/ijc.27947 contributor: fullname: Xing – volume: 127 start-page: 1078 year: 2004 ident: ref23 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(03)01321-7 contributor: fullname: Denlinger – volume: 392 start-page: 190 year: 2010 ident: ref9 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2010.01.011 contributor: fullname: Liu – volume: 68 start-page: 394 year: 2018 ident: ref1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 contributor: fullname: Bray – volume: 12 start-page: 1247 year: 2007 ident: ref6 publication-title: Oncologist doi: 10.1634/theoncologist.12-10-1247 contributor: fullname: Mann – volume: 76 start-page: 4916 year: 2016 ident: ref17 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1974 contributor: fullname: Tew – volume: 68 start-page: 483 year: 2014 ident: ref11 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2014.03.011 contributor: fullname: Zhou – volume: 9 start-page: 265 year: 2009 ident: ref36 publication-title: Nat Rev Cancer doi: 10.1038/nrc2620 contributor: fullname: Polyak – volume: 11 start-page: 7644 year: 2019 ident: ref25 publication-title: Am J Transl Res contributor: fullname: Xu – volume: 10 start-page: 2567 year: 2018 ident: ref13 publication-title: Am J Transl Res contributor: fullname: Mao – volume: 15 start-page: 1195 year: 2014 ident: ref8 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70440-1 contributor: fullname: San-Miguel |
SSID | ssj0066824 |
Score | 2.3011756 |
Snippet | The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines.
First, the sensitivity... PURPOSEThe aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. MATERIALS AND... Wanjun Zhang,1,* Junwei Niu,1,* Yongcheng Ma,2 Xiawan Yang,1 Huixia Cao,3 Honggang Guo,1 Fengchang Bao,1 Ahmed Haw,1 Yuqing Chen,1 Kai Sun1 1Department of... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 3823 |
SubjectTerms | bortezomib chidamide combination drug therapy gastric cancer Original Research |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PT9swFLYmDmiXicEYGWMyUq8ZcZzE7rFUQIXUXdpJ3IJ_ihyaoK49bH8979lp1SIkLrvakWK9z_b7Yfv7CBlY6VQhhqheBrlJ4X2ZqlxmqeXgq7XytnJYh5z-qia_i_uH8mFH6gvvhEV64Gi4KwYu0plCF6VWheNWGWu59D5nvHSOubD7snKTTMU9uKpklLNlkCOh2F98mYeaPFeQKf-cRV6wPV8UKPvfijNfX5fc8T-3R-RTHzjSURzwZ_LBtcfkcNofjZ-QRwCczv7iU77AvUxH-AB3veiWdGSiRATtPB0_NVYtGuto01LYDCAxDthQLMhSFFd3_7pFoyk03SkU9TB0jDNj-YXMb2_m40nayyekBhbWKjWZ1JllKvelszoXxnDBSqWYZXgBU6lK2Ep4brmSQ62l9mBhIaFTZcoO-Sk5aLvWnRFqdCGEz2QQ6qm4H3I8TXOcWeNzkcuEDDZ2rJ8jSUYNyQWauwZz1725E3KNNt5-gszWoQHwrnu86_fwTsjlBqEaVgIeb6jWdes_NcYmIUHMEvI1Irb9FYSNBdZ2EiL2sNwby35P2zwFtm2BnHe5-PY_Bn9OPuaYr4cSzndysFqu3QUENSv9I8zfF56_9wk priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6VIiEuqLwDBRmp15T4kdh7QNV2RamQlktbqbfgJ43UTSDdlSi_Ho-TXbFVj1ydWLFmPPF8M575AA6c8lrICbKXRWwiQihzzVSROx7PaqODqzzGIeffqtML8fWyvNyBNRnnKMCbe6Ed8kld9NeHv3_dHkWD_4TXmKmQHyP2PTwbOn09gIdMcIFbfS426YSqUgO7LY2QCbn_hkK9u5O3jqbUwf8-t_Pu7cl_jqOTPXgy-pFkOij-Kez49hk8mo-Z8ufwPeqfnN1iZV9qxUymWI-7WnQ9mdqBMYJ0gcyuGqcXjfOkaUn8N0ScnFRFMD5LkGvd_-kWjSFx6ItGjg9LZrhR-hdwfvL5fHaaj2wKuY12tsxtoUzhqGah9M4waS2XtNSaOor3MbWupKtk4I5rNTFGmWA01qFKqgvtJvwl7LZd618DsUZIGQqVeHsqHiYck2ueU2cDk0xlcLCWY_1z6JlRR6yB4q6juOtR3Bkco4w3r2Cj6zTQ9T_q0W5qGj0kb4URZVyN505b57gKgVFeek99Bh_WGqqjYWC2Q7e-W93U6KokvFhk8GrQ2OZT0YsUGOrJQG7pcmst20_a5io135bYAo_JN_9j8W_hMUP4niI6-7C77Ff-XfRxluZ92r9_AXjj_M4 priority: 102 providerName: Scholars Portal |
Title | The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32440150 https://search.proquest.com/docview/2406301440 https://pubmed.ncbi.nlm.nih.gov/PMC7213427 https://doaj.org/article/1658ec4b45ba4e3dacdd38ff2135ee1e |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB6SFEIupe-qD7OFXGVLWkm7PjomaSg4hCYF39R9NoJKCq59aH99Z1ZSqEtPveiwktAy36x2vtl5AJxa6VQu5tS9DLlJ7n0Rq0wmseW4V2vlbenID7m6Ki-_5J_WxfoAijEXJgTtG11P2-_NtK3vQmzlfWNmY5zY7Hq1FFSGDDn7IRwKzkeK3v9-y1JmeZ-IRy14ZkiMpzd9GbATOEbzISeOv7cLhWL9_7Iw_w6U_GPnuXgCjweTkS36qT2FA9c-g-PVcCj-HL4i1OzmJyXxharLbEGpt7um27CF6ZtDsM6z5V1tVVNbx-qW4W8AKXFAhZErllFbdfera2rNcOijonYehi1JJzYv4Pbi_HZ5GQ-NE2KDS2obm0TqxKYq84WzOhPGcJEWSqU2pdBLpUphS-G55UrOtZbaa0UppyJVibJz_hKO2q51r4EZnQvhExla9JTczzmdozmeWuMzkckITkc5Vvd9eYwKaQVJvkLJV4PkIzgjGT88QjWtw0C3-VYNyFYpGkPO5DovcDaOW2Ws5dJ7BLtwLnURfBgRqnAN0MGGal23-1GRVRKoYRLBqx6xh0-NiEcg9rDcm8v-HVS7UGd7ULM3__3mWzjJiJ4Hj807ONpudu492jBbPUHNXYsJPDo7v7r-PAmeALyucjkJ2vwb6Qr4TA |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27957,27958,31755,33780,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIpVeeEPD00i9ZjeJkzh7XFaUBboVUhfUW_CTRjRJtewe6K9nxkkqtuICVztRHH9je77xPAAOTWFlKiZUvQy5SepcFsqkiELD8axW0pnckh1ycZLPv6Qfz7KzHciGWBjvtK9VNWou6lFTnXvfystajwc_sfHnxUxQGjLk7LfgNq7XRAwkvduA87xI0i4Uj4rwjJEaj067RGD7sIcKREosf-sc8un6_6Zj3nSV_OPsOboHX4dRdy4nP0abtRrpqxsJHf_5t-7D3V4bZdOu-wHs2OYh7C36-_ZH8A2liJ3-ovhAn9CZTSmqd1O3KzbVXd0J1jo2O6-MrCtjWdUw3GGQbXvAGVl5GVVst1dtXSmGTe8lVQrRbEbitnoMy6N3y9k87GsyhBpX6zrUUaEiE8vEZdaoRGjNRZxJGZuYvDqlzIXJheOGy2KiVKGckhTNKmIZSTPhT2C3aRt7AEyrVAgXFb76T87dhNMVneWx0S4RSRHA4QBQedll3iiRsRCkJUJa9pAG8JbAu36E0mX7hnb1vexnt4xRz7I6VWmGo7HcSG0ML5zDCc-sjW0AbwboS1xedGciG9tufpak8HjWGQXwtBOF608NohSA2BKSrbFs9yD0PoV3D_Wz_37zNdyZLxfH5fGHk0_PYT8hK4A3DL2A3fVqY1-iqrRWr_zC-A2_hxX9 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb5wwFH5qU2mUS_eFrq6UKwxgwOY4nXaaLhNFSipFvVCvDWqB0XTm0Pz6-hmIMlFPuRojjL9n-33PbwE40NyIjJVYvcxxk8zaPBQpj0NN3VkthdWFQTvk8qg4_JZ9PsvPrpT68k77StZR-7uJ2vrc-1auGjUd_cSmx8s5wzRkjrOvtJ3ehjtuzablSNT7TbgoeJr14XhYiGfq6HF00icD24eJUyIyZPo7Z5FP2f8_PfO6u-SV82dxD76PI-_dTn5F242M1MW1pI43-rX7cHfQSsms7_IAbpn2IUyWw737I_jhpImc_MU4QZ_YmcwwunfbdGsyU339CdJZMj-vtWhqbUjdErfTONbtgSdo7SVYud1cdE0tiWv6KLBiiCJzFLv1YzhdfDidH4ZDbYZQuVW7CVXMZawTkdrcaJkypShLciESnaB3pxAF0wWzVFPBSym5tFJgVCtLRCx0SZ_AXtu15hkQJTPGbMx9FaCC2pLiVZ2hiVY2ZSkP4GAEqVr1GTgqx1wQ1srBWg2wBvAOAbzsgmmzfUO3_lkNM1wlTt8yKpNZ7kZjqBZKa8qtdZOeG5OYAN6O8FdumeHdiWhNt_1ToeLj2WccwNNeHC4_NYpTAGxHUHbGsvvEwe9TeQ9wP7_xm29gcvx-UX39dPTlBeynaAzw9qGXsLdZb80rpzFt5Gu_Nv4BY7sYfQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Synergistic+Antitumor+Activity+of+Chidamide+in+Combination+with+Bortezomib+on+Gastric+Cancer&rft.jtitle=OncoTargets+and+therapy&rft.au=Zhang+W&rft.au=Niu+J&rft.au=Ma+Y&rft.au=Yang+X&rft.date=2020-01-01&rft.pub=Dove+Medical+Press&rft.issn=1178-6930&rft.eissn=1178-6930&rft.volume=13&rft.spage=3823&rft.epage=3837&rft_id=info:doi/10.2147%2FOTT.S240721&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1658ec4b45ba4e3dacdd38ff2135ee1e |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6930&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6930&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6930&client=summon |